Serial Liquid Biopsies Allow for Tracking of Resistance Mutations in GI Cancers
Pashtoon M. Kasi, MBBS, MD, MS, clinical assistant professor of internal medicine, University of Iowa Carver College of Medicine, discusses how serial testing via liquid biopsies in patients with gastrointestinal cancers can provide oncologists with a better picture of the patient’s condition and potential acquired mechanisms of resistance.
Pashtoon M. Kasi, MBBS, MD, MS, clinical assistant professor of internal medicine, University of Iowa Carver College of Medicine, discusses how serial testing via liquid biopsies in patients with gastrointestinal cancers can provide oncologists with a better picture of the patient’s condition and potential acquired mechanisms of resistance. He explains that multiple liquid biopsies are especially helpful for the management of colorectal cancer when patients progress on anti-EGFRtherapies to identify and track potential acquiredRASmutations.
Kasi lead a study of 322 patients in which serial biopsies were conducted to monitor potential changes in each patient’s disease using the Guardant360 assay. In the study, researchers were able to identifyRAS/RAFwild type(n = 214),RASmutations (n = 83),BRAF V600E mutations(n = 18), nonBRAFV600Emutations (n = 7),HER2amplifications (n = 13),HER2mutations (n = 7), and microsatellite instabilityhigh (n = 3). Recognizing these alterations helped with treatment modification and clinical trial selection for these patients.
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
